Both epidemiology and laboratory data can contribute to estimates of risks to humans of exposure to low doses of carcinogens. The sum of all these contributions does not permit us to make these ...
Pfizer released full tafamidis data demonstrating a 30% reduction (29.5% vs 42.9%) in the risk of all-cause mortality and a 32% reduction in CV-related hospitalizations. The market has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback